Purple Biotech CEO Gil Efron to Step Down in August 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Purple Biotech announced that Gil Efron, CEO, will step down from his role as CEO effective August 2026. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed. The Board of Directors has initiated a formal search process to appoint a new CEO The Board of Directors has initiated a search process to identify a new CEO with experience leading innovative biotechnology companies and advancing novel therapeutic platforms. Mr. Efron will continue to serve as CEO until August 2026 or until a successor is appointed, ensuring a smooth and orderly leadership transition. Mr. Efron has also been appointed to the Board of Directors, to serve as a second class director, effective immediately and until the annual general meeting of shareholders of the Company to be held in 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PPBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PPBT
Wall Street analysts forecast PPBT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.810
Low
34.00
Averages
34.00
High
34.00
Current: 2.810
Low
34.00
Averages
34.00
High
34.00
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Purple Biotech Reports Q1 2026 Financial Results
- Financial Overview: Purple Biotech reported a GAAP EPS of -$0.09 for Q1 2026, indicating ongoing challenges in profitability, which may lead to cautious market sentiment regarding its future prospects.
- Adjusted Net Loss: The adjusted net loss for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million compared to $1.3 million in the same period of 2025, reflecting pressures on cost control and revenue growth that could impact investor confidence.
- Cash Position: As of March 31, 2026, Purple Biotech had cash and cash equivalents totaling $6.4 million, which is expected to provide a cash runway into 2027, ensuring continued investment in R&D and market initiatives.
- Non-GAAP EPS: The company reported a non-GAAP EPS of $19.85, which, while potentially attracting investor interest, contrasts sharply with GAAP figures, highlighting discrepancies in financial transparency and profitability that could affect long-term stock performance.
See More
PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
New Advisory Board Established: Purple Biotech Ltd has formed a scientific advisory board for its CAPT-N-3 antibody platform.
Focus on Antibody Development: The board will provide expertise and guidance to enhance the development of the CAPT-N-3 antibody platform.
See More
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
Purple Biotech CEO Gil Efron to Step Down in August 2026
- Executive Transition: Purple Biotech announced that CEO Gil Efron will step down in August 2026, marking the end of his eight-year tenure in senior leadership roles, including Chief Financial Officer and CEO, indicating a significant shift in the company's leadership structure.
- Leadership Experience: Efron has served as CEO since 2022, during which the company underwent several strategic adjustments; while specific performance metrics are not disclosed, his decisions will have lasting implications for the company's future trajectory.
- Market Reaction: This announcement may raise investor concerns regarding the company's future direction, particularly during the leadership transition, which could impact stock prices and market confidence, necessitating close monitoring of subsequent leadership selection.
- Strategic Planning: Purple Biotech must establish a clear succession plan following Efron's departure to ensure continuity and stability in its strategic initiatives, mitigating potential disruptions to business operations due to leadership changes.
See More
Purple Biotech Reports Q1 2026 Financial Results
- Financial Overview: Purple Biotech reported a GAAP EPS of -$0.09 for Q1 2026, indicating ongoing challenges in profitability, which may lead to cautious market sentiment regarding its future prospects.
- Adjusted Net Loss: The adjusted net loss for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million compared to $1.3 million in the same period of 2025, reflecting pressures on cost control and revenue growth that could impact investor confidence.
- Cash Position: As of March 31, 2026, Purple Biotech had cash and cash equivalents totaling $6.4 million, which is expected to provide a cash runway into 2027, ensuring continued investment in R&D and market initiatives.
- Non-GAAP EPS: The company reported a non-GAAP EPS of $19.85, which, while potentially attracting investor interest, contrasts sharply with GAAP figures, highlighting discrepancies in financial transparency and profitability that could affect long-term stock performance.
See More
PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
New Advisory Board Established: Purple Biotech Ltd has formed a scientific advisory board for its CAPT-N-3 antibody platform.
Focus on Antibody Development: The board will provide expertise and guidance to enhance the development of the CAPT-N-3 antibody platform.
See More
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
Purple Biotech CEO Gil Efron to Step Down in August 2026
- Executive Transition: Purple Biotech announced that CEO Gil Efron will step down in August 2026, marking the end of his eight-year tenure in senior leadership roles, including Chief Financial Officer and CEO, indicating a significant shift in the company's leadership structure.
- Leadership Experience: Efron has served as CEO since 2022, during which the company underwent several strategic adjustments; while specific performance metrics are not disclosed, his decisions will have lasting implications for the company's future trajectory.
- Market Reaction: This announcement may raise investor concerns regarding the company's future direction, particularly during the leadership transition, which could impact stock prices and market confidence, necessitating close monitoring of subsequent leadership selection.
- Strategic Planning: Purple Biotech must establish a clear succession plan following Efron's departure to ensure continuity and stability in its strategic initiatives, mitigating potential disruptions to business operations due to leadership changes.
See More
